|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.07.26 - 06:30
|
ANTENGENE-B Receives USD60 million Upfront Payment from UCB (AAStocks)
|
|
|
ANTENGENE-B (06996.HK) announced that, under the global exclusive licensing agreement reached with UCB for the CD19/CD3 bispecific T-cell engager (TCE) antibody ATG-201, it has received the first upfront payment of USD60 million from the company. The company expects the payment to further strengthen the group's cash position, pr......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.06.26 - 14:06
|
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines (Business Wire)
|
|
|
Financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors
Proceeds will support clinical advancement of lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD)
SAN FRANCISCO--(BUSINESS WIRE)--#biotech--SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.
The financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors ARCH Ventur...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
